Chang C.-H.Wu H.-C.RUOH-FANG YENKao A.Lin C.-C.Lee C.-C.2020-09-232020-09-2320020250-7005https://scholars.lib.ntu.edu.tw/handle/123456789/514556Tissue polypeptide specific antigen (TPS) is a new tumor marker that indicates tumor proliferative rate rather than tumor burden. The purpose of this study was to assess the clinical value of TPS in patients with renal cell carcinoma (RCC). Serum levels of TPS were measured in 30 patients with locoregional and in 20 patients with advanced disease before and after therapy. The results showed that: (1) the detection sensitivity of TPS for RCC is 60.0%; (2) the detection sensitivity of TPS in advanced RCC (100. 0%) was significantly higher than in locoregional RCC (33.3%); (3) the 10 locoregional RCC patients without recurrence had normal serum TPS levels during a follow-up period of 1 year; and (4) the 8 advanced RCC patients with good response during therapy had normal serum TPS levels, while 12 patients with poor disease had significantly elevated serum TPS levels during a follow-up period of 1 year. Our results suggest that TPS may have a potential clinical role as a valuable tumor marker for RCC, especially in advanced diseases and follow-up therapy response.Renal cell carcinoma (RCC); Tissue polypeptide specific antigen (TPS)[SDGs]SDG3tissue polypeptide antigen; tumor marker; adult; advanced cancer; aged; antigen binding; antigen specificity; article; cancer recurrence; cell proliferation; clinical article; controlled study; diagnostic accuracy; diagnostic value; female; follow up; human; kidney carcinoma; male; priority journal; statistical significance; Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Peptides; Sensitivity and Specificity; Tumor Markers, Biologicaljournal article125300232-s2.0-0036765648